Mounjaro on the NHS: Eligibility, Referrals and Access Explained

Mounjaro on the NHS is a topic of growing interest as tirzepatide becomes available through specialist weight management services in England following NICE approval in 2024. However, access remains tightly restricted, with prescriptions issued only through Tier 3 and Tier 4 pathways rather than routine GP prescribing. Eligibility depends on specific BMI and comorbidity criteria, and rollout across integrated care boards has been uneven. This article explains who currently qualifies, how to seek a referral, and why NHS prescriptions remain limited despite formal regulatory and clinical endorsement.

Is Mounjaro available on the NHS yet?

Mounjaro is available on the NHS in England through specialist weight management services following NICE approval in 2024, but it is not yet accessible via routine GP prescribing and rollout across integrated care boards remains phased and uneven.

Mounjaro (tirzepatide) is available on the NHS in England, but access remains tightly restricted and is not yet widely available through standard GP prescribing. The MHRA has authorised Mounjaro in the UK both for the management of type 2 diabetes and for chronic weight management in adults.^[1][2] NICE subsequently recommended tirzepatide for use within NHS England's specialist weight management services through its technology appraisal TA1026, published in 2024. However, a NICE recommendation does not automatically mean a medicine is immediately accessible to all eligible patients: local integrated care boards (ICBs) in England commission services and allocate funding, and rollout has been phased and uneven across regions.

In Scotland, NHS Scotland commissions weight management services separately, and access to tirzepatide is determined through the Scottish Medicines Consortium (SMC) process. NHS Wales and Health and Social Care in Northern Ireland operate their own commissioning frameworks, so availability differs across the four nations. Patients in Wales, Scotland and Northern Ireland should contact their GP or local health board to understand what is currently commissioned in their area.

For patients in England, Mounjaro is currently being introduced through NHS specialist Tier 3 and Tier 4 weight management services rather than through routine GP prescribing. This means that even where NICE guidance supports its use, a patient must first be referred into a specialist pathway before a prescription can be considered. The pace of that rollout is discussed further in the sections below.

Which NHS patients qualify for Mounjaro under current NICE guidance?

NICE TA1026 recommends tirzepatide for adults with a BMI of at least 35 kg/m² and one weight-related comorbidity, or a BMI of 30 kg/m² or above in certain higher-risk ethnic groups, delivered within a specialist service for up to two years.

Under NICE technology appraisal TA1026, tirzepatide is recommended for adults in England who meet specific clinical criteria, and it is not available to everyone who wishes to lose weight. The criteria require that a patient has a BMI of at least 35 kg/m² alongside at least one weight-related comorbidity, such as type 2 diabetes, hypertension, obstructive sleep apnoea or cardiovascular disease. NICE also allows tirzepatide to be considered at a lower BMI threshold in certain higher-risk groups, including people from South Asian, Chinese, Black African or African-Caribbean backgrounds, where a BMI of 30 kg/m² or above may be sufficient, reflecting the different risk profiles associated with body composition in those populations.

In addition to the BMI and comorbidity criteria, NICE guidance specifies that tirzepatide should be used as part of a specialist weight management service that provides dietary, physical activity and behavioural support. It is not intended as a standalone prescription. Treatment duration is time-limited under the appraisal: NICE recommends a maximum treatment period of two years, and prescribing should only continue where the patient is responding to treatment and where ongoing specialist support is in place.^[3][5] The TA also specifies stopping criteria: treatment should be discontinued if a patient has not achieved a meaningful weight-loss response at the defined review point as set out in the appraisal.^[5][6]

Patients with type 2 diabetes who are already under the care of a diabetes specialist may have a separate route to tirzepatide through that clinical pathway, as Mounjaro also holds a licence for glycaemic management. Eligibility in that context is governed by separate NICE guidance relating to diabetes management. Anyone uncertain about which criteria apply to them should discuss their individual circumstances with their GP or specialist.

How do you get referred to an NHS specialist weight management service?

In England, access to specialist Tier 3 weight management services, where tirzepatide may be prescribed, begins with a GP referral, as most areas do not permit self-referral; criteria and waiting times vary between integrated care boards.

In England, the route to an NHS specialist weight management service begins with a GP referral, and in most areas patients cannot self-refer directly into Tier 3 or Tier 4 services, though local arrangements may vary. Tier 3 services provide intensive, multidisciplinary support including dietetic input, psychological support and medical review, and it is within these services that medicines such as tirzepatide may be prescribed. Tier 4 services are reserved for patients being considered for bariatric surgery. A GP will typically assess whether a patient meets the referral threshold for their local ICB before making a referral, and criteria can vary between ICBs across England.

Bolt Pharmacy is a GPhC-registered online pharmacy offering weight-management consultations, where a prescriber may consider Mounjaro as one possible option following a clinical assessment, and only where it is clinically appropriate for that individual. The GPhC regulates pharmacy premises in Great Britain; in Northern Ireland, pharmacy regulation is the responsibility of the Pharmaceutical Society of Northern Ireland (PSNI).

To support a referral, a GP will usually want to review a patient's weight history, any previous attempts at lifestyle intervention, current comorbidities and relevant blood tests. Patients can help this process by keeping a record of previous weight management efforts and any relevant diagnoses. NHS England has published service specifications for specialist weight management (Tier 3) and bariatric surgery (Tier 4) services, and patients can ask their GP whether a commissioned Tier 3 service exists in their area.

In Scotland, NHS Scotland's weight management pathways are commissioned by regional health boards, and referral routes differ from those in England. In Wales, Local Health Boards commission specialist obesity services, and in Northern Ireland, Health and Social Care Trusts manage access. Patients in these nations should speak to their GP about what specialist services are available locally, as the structure and waiting times vary considerably.

Why are so few NHS prescriptions being issued despite NICE approval?

NICE approval does not create the services or funding needed to deliver treatment; limited Tier 3 capacity, workforce shortages and inconsistent ICB commissioning mean many eligible patients cannot yet access Mounjaro through the NHS in practice.

Despite NICE recommending tirzepatide for NHS use in England, the number of prescriptions being issued through the NHS remains low because the infrastructure needed to deliver treatment at scale is not yet in place. NICE approval establishes that a treatment is clinically and cost-effective, but it does not create the services, staff or funding required to deliver it. NHS England has committed to a phased rollout of weight management medicines through specialist services, but Tier 3 services are limited in number, have significant waiting lists in many areas, and are not uniformly commissioned across all ICBs in England.

Funding is a central constraint. ICBs in England are responsible for commissioning Tier 3 services and for allocating budgets to cover the cost of medicines within those services. Where an ICB has not yet established or expanded its specialist weight management pathway, patients who meet the NICE criteria may still be unable to access treatment through the NHS in practice. NHS England has published implementation guidance to support ICBs in rolling out weight management medicines, but the pace of that implementation varies.

Workforce capacity is a further limiting factor. Tier 3 services require dietitians, psychologists, specialist nurses and physicians working together, and recruiting and retaining those staff takes time. Patients who are waiting for an NHS referral or who have been told their local service is not yet commissioned should ask their GP to document the referral request and to review the position again if local commissioning changes. Suspected adverse effects of any medicine should be reported through the MHRA Yellow Card scheme, which can be accessed at yellowcard.^[10]mhra.gov.uk.

Frequently Asked Questions